Generic VEL/SOF With or Without RBV for HIV/HCV Coinfected Patients
Status:
Completed
Trial end date:
2017-10-31
Target enrollment:
Participant gender:
Summary
Data are limited regarding the effectiveness and safety of generic velpatasvir plus
sofosbuvir (VEL/SOF) with or without ribavirin (RBV) for the treatment of hepatitis C virus
(HCV) in patients with human immunodeficiency virus (HIV) coinfection. We aim to compare the
effectiveness and safety of VEL/SOF with and without RBV for 12 weeks in HIV/HCV-coinfected
and HCV-monoinfected patients The antiviral responses and the adverse events (AEs) are
compare between the two groups. The characteristics potentially related to sustained
virologic response 12 weeks off therapy (SVR12) are analyzed.